U.S., Feb. 25 -- ClinicalTrials.gov registry received information related to the study (NCT06841445) titled 'Efficacy and Safety of HRS9531 Tablet in Obese Subjects' on Feb. 18.
Brief Summary: To evaluate the efficacy of HRS9531 tablet compared with placebo in reducing body weight in obese subjects after 26 weeks of treatment.
Study Start Date: March, 2025
Study Type: INTERVENTIONAL
Condition:
Chronic Management of Body Weight
Intervention:
DRUG: HRS9531 Tablet
HRS9531 Tablet dose 1
DRUG: HRS9531 Tablet
HRS9531 Tablet dose 2
DRUG: HRS9531 Tablet
HRS9531 Tablet dose 3
DRUG: HRS9531 Tablet placebo
HRS9531 Tablet placebo
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Fujian Shengdi Pharmaceutical Co., Ltd.
Published by HT Dig...